Matching articles for "ustekinumab"
Risankizumab (Skyrizi) for Ulcerative Colitis
The Medical Letter on Drugs and Therapeutics • November 11, 2024; (Issue 1715)
The injectable interleukin (IL)-23 antagonist
risankizumab-rzza (Skyrizi – Abbvie), previously
approved by the FDA for treatment of Crohn's disease
(CD), has now been approved for treatment of
moderately...
The injectable interleukin (IL)-23 antagonist
risankizumab-rzza (Skyrizi – Abbvie), previously
approved by the FDA for treatment of Crohn's disease
(CD), has now been approved for treatment of
moderately to severely active ulcerative colitis (UC)
in adults. Risankizumab is the first IL-23 antagonist
to be approved for treatment of both CD and UC. It is
also approved for treatment of plaque psoriasis and
psoriatic arthritis.
Drugs for Plaque Psoriasis
The Medical Letter on Drugs and Therapeutics • September 30, 2024; (Issue 1712)
Mild to moderate plaque psoriasis can be treated
with topical drugs and phototherapy. Patients
with moderate to severe disease generally require
systemic therapy. Guidelines for the treatment of
psoriasis...
Mild to moderate plaque psoriasis can be treated
with topical drugs and phototherapy. Patients
with moderate to severe disease generally require
systemic therapy. Guidelines for the treatment of
psoriasis with topical therapy, phototherapy, and
systemic drugs have recently been published.
Comparison Table: Some Drugs for Plaque Psoriasis (online only)
The Medical Letter on Drugs and Therapeutics • September 30, 2024; (Issue 1712)
...
View the Comparison Table: Some Drugs for Plaque Psoriasis
In Brief: Wezlana — An Ustekinumab Biosimilar Interchangeable with Stelara
The Medical Letter on Drugs and Therapeutics • July 22, 2024; (Issue 1707)
The FDA has approved ustekinumab-auub (Wezlana –
Amgen), an interchangeable biosimilar product similar
to the interleukin-12 and -23 antagonist Stelara, for
treatment of the same indications as Stelara...
The FDA has approved ustekinumab-auub (Wezlana –
Amgen), an interchangeable biosimilar product similar
to the interleukin-12 and -23 antagonist Stelara, for
treatment of the same indications as Stelara (see
Table 1). Wezlana is the first Stelara biosimilar to be
approved in the US.
Mirikizumab (Omvoh) for Ulcerative Colitis
The Medical Letter on Drugs and Therapeutics • March 18, 2024; (Issue 1698)
The FDA has approved the interleukin (IL)-23
antagonist mirikizumab-mrkz (Omvoh – Lilly) for
treatment of moderately to severely active ulcerative
colitis (UC) in adults. Mirikizumab is the first...
The FDA has approved the interleukin (IL)-23
antagonist mirikizumab-mrkz (Omvoh – Lilly) for
treatment of moderately to severely active ulcerative
colitis (UC) in adults. Mirikizumab is the first selective
IL-23 antagonist to be approved for this indication.
Ustekinumab (Stelara), an IL-12/23 antagonist, was
approved for treatment of UC in 2019. The IL-23
antagonist risankizumab (Skyrizi) is approved for
treatment of Crohn's disease.
Bimekizumab (Bimzelx) for Psoriasis
The Medical Letter on Drugs and Therapeutics • January 22, 2024; (Issue 1694)
The FDA has approved the injectable interleukin (IL)-17A/17F antagonist bimekizumab-bkzx (Bimzelx
– UCB) for treatment of moderate to severe plaque
psoriasis in adults who are candidates for...
The FDA has approved the injectable interleukin (IL)-17A/17F antagonist bimekizumab-bkzx (Bimzelx
– UCB) for treatment of moderate to severe plaque
psoriasis in adults who are candidates for systemic
treatment or phototherapy. Bimekizumab is the first
IL-17A/17F antagonist to be approved in the US. It
was approved in the European Union for the same
indication in 2021.
Etrasimod (Velsipity) for Ulcerative Colitis
The Medical Letter on Drugs and Therapeutics • November 27, 2023; (Issue 1690)
The oral sphingosine 1-phosphate (S1P) receptor
modulator etrasimod (Velsipity – Pfizer) has been
approved by the FDA for treatment of moderately to
severely active ulcerative colitis in adults. It is...
The oral sphingosine 1-phosphate (S1P) receptor
modulator etrasimod (Velsipity – Pfizer) has been
approved by the FDA for treatment of moderately to
severely active ulcerative colitis in adults. It is the
second oral S1P receptor modulator to be approved
in the US for this indication; ozanimod (Zeposia) was
the first.
Drugs for Inflammatory Bowel Disease
The Medical Letter on Drugs and Therapeutics • July 10, 2023; (Issue 1680)
Ulcerative colitis (UC) and Crohn's disease (CD),
referred to collectively as inflammatory bowel disease
(IBD), are chronic immune-mediated inflammatory
conditions. Guidelines for treatment of UC and...
Ulcerative colitis (UC) and Crohn's disease (CD),
referred to collectively as inflammatory bowel disease
(IBD), are chronic immune-mediated inflammatory
conditions. Guidelines for treatment of UC and CD
have been updated in recent years
Expanded Table: Some Drugs for Inflammatory Bowel Disease (online only)
The Medical Letter on Drugs and Therapeutics • July 10, 2023; (Issue 1680)
...
View the Table: Some Drugs for Inflammatory Bowel Disease
Table: Safety of Drugs for IBD in Pregnancy (online only)
The Medical Letter on Drugs and Therapeutics • July 10, 2023; (Issue 1680)
...
View the Table: Safety of Drugs for IBD in Pregnancy
Table: Some Drug Interactions with Drugs for IBD (online only)
The Medical Letter on Drugs and Therapeutics • July 10, 2023; (Issue 1680)
...
View the Table: Some Drug Interactions with Drugs for IBD
Risankizumab (Skyrizi) - An IL-23 Antagonist for Crohn's Disease
The Medical Letter on Drugs and Therapeutics • December 26, 2022; (Issue 1666)
The injectable interleukin (IL)-23 antagonist
risankizumab-rzaa (Skyrizi – Abbvie) has been
approved by the FDA for treatment of moderately
to severely active Crohn's disease (CD) in adults.
Risankizumab...
The injectable interleukin (IL)-23 antagonist
risankizumab-rzaa (Skyrizi – Abbvie) has been
approved by the FDA for treatment of moderately
to severely active Crohn's disease (CD) in adults.
Risankizumab was approved earlier for treatment of
plaque psoriasis and psoriatic arthritis.
Upadacitinib (Rinvoq): A Second JAK Inhibitor for Ulcerative Colitis
The Medical Letter on Drugs and Therapeutics • September 5, 2022; (Issue 1658)
The FDA has approved the oral Janus kinase (JAK)
inhibitor upadacitinib (Rinvoq – Abbvie) for treatment
of moderately to severely active ulcerative colitis in
adults who have had an inadequate response to...
The FDA has approved the oral Janus kinase (JAK)
inhibitor upadacitinib (Rinvoq – Abbvie) for treatment
of moderately to severely active ulcerative colitis in
adults who have had an inadequate response to or
cannot tolerate one or more tumor necrosis factor
(TNF) inhibitors. Upadacitinib is the second JAK
inhibitor to be approved for this indication; tofacitinib
(Xeljanz) was the first. Upadacitinib is also approved
for treatment of rheumatoid arthritis, psoriatic
arthritis, atopic dermatitis, and ankylosing spondylitis.
Ozanimod (Zeposia) for Ulcerative Colitis
The Medical Letter on Drugs and Therapeutics • September 20, 2021; (Issue 1633)
The oral sphingosine 1-phosphate (S1P) receptor
modulator ozanimod (Zeposia – Bristol Myers Squibb)
has been approved by the FDA for treatment of adults
with moderately to severely active ulcerative...
The oral sphingosine 1-phosphate (S1P) receptor
modulator ozanimod (Zeposia – Bristol Myers Squibb)
has been approved by the FDA for treatment of adults
with moderately to severely active ulcerative colitis. It
is the first S1P receptor modulator to be approved for
treatment of ulcerative colitis. Ozanimod was approved
in March 2020 for use in adults with relapsing forms of
multiple sclerosis.
Drugs for Atopic Dermatitis
The Medical Letter on Drugs and Therapeutics • June 15, 2020; (Issue 1600)
Atopic dermatitis (AD; also known as eczema) is
frequently associated with other atopic disorders
such as allergic rhinitis, asthma, and food allergy. It
commonly presents in infancy and early childhood
and...
Atopic dermatitis (AD; also known as eczema) is
frequently associated with other atopic disorders
such as allergic rhinitis, asthma, and food allergy. It
commonly presents in infancy and early childhood
and has a relapsing course, often improving by
adolescence, but sometimes persisting into (or first
appearing in) adulthood or even old age.
Drugs for Psoriatic Arthritis
The Medical Letter on Drugs and Therapeutics • December 30, 2019; (Issue 1588)
Psoriatic arthritis is a chronic inflammatory
arthropathy associated with psoriasis. A recent review
found that about 20% of patients with psoriasis have
psoriatic arthritis. Updated guidelines for...
Psoriatic arthritis is a chronic inflammatory
arthropathy associated with psoriasis. A recent review
found that about 20% of patients with psoriasis have
psoriatic arthritis. Updated guidelines for treatment
of psoriatic arthritis have recently been published.
Drugs for Psoriasis
The Medical Letter on Drugs and Therapeutics • June 17, 2019; (Issue 1574)
Mild to moderate psoriasis can be treated with topical
drugs or with phototherapy. Patients with moderate to
severe disease generally require systemic...
Mild to moderate psoriasis can be treated with topical
drugs or with phototherapy. Patients with moderate to
severe disease generally require systemic therapy.
Expanded Table: Some Drugs for Psoriasis (online only)
The Medical Letter on Drugs and Therapeutics • June 17, 2019; (Issue 1574)
...
View the Expanded Table: Some Drugs for Psoriasis
Risankizumab (Skyrizi) for Psoriasis
The Medical Letter on Drugs and Therapeutics • June 3, 2019; (Issue 1573)
The FDA has approved the interleukin (IL)-23
antagonist risankizumab-rzaa (Skyrizi – Abbvie) for
treatment of moderate to severe plaque psoriasis in
adults. Risankizumab is the third IL-23 antagonist...
The FDA has approved the interleukin (IL)-23
antagonist risankizumab-rzaa (Skyrizi – Abbvie) for
treatment of moderate to severe plaque psoriasis in
adults. Risankizumab is the third IL-23 antagonist to
be approved for this indication; guselkumab (Tremfya)
and tildrakizumab (Ilumya) were approved earlier.
Tildrakizumab (Ilumya) - Another IL-23 Antagonist for Psoriasis
The Medical Letter on Drugs and Therapeutics • January 14, 2019; (Issue 1563)
Tildrakizumab-asmn (Ilumya – Sun), an interleukin
(IL)-23 antagonist, has been approved by the FDA for
treatment of adults with moderate to severe plaque
psoriasis who are candidates for systemic therapy...
Tildrakizumab-asmn (Ilumya – Sun), an interleukin
(IL)-23 antagonist, has been approved by the FDA for
treatment of adults with moderate to severe plaque
psoriasis who are candidates for systemic therapy or
phototherapy. Tildrakizumab is the second selective
IL-23 antagonist to be approved for this indication;
guselkumab (Tremfya) was the first.
Drugs for Inflammatory Bowel Disease
The Medical Letter on Drugs and Therapeutics • July 2, 2018; (Issue 1550)
Management of both ulcerative colitis (UC) and Crohn's
disease (CD) is based on disease severity. Disease
location (proctitis, left-sided colitis, or extensive
colitis) also plays a role in drug selection....
Management of both ulcerative colitis (UC) and Crohn's
disease (CD) is based on disease severity. Disease
location (proctitis, left-sided colitis, or extensive
colitis) also plays a role in drug selection. Some
drugs for induction and maintenance of remission of
inflammatory bowel disease (IBD) are listed in Table 1.
Expanded Table: Some Drugs for Inflammatory Bowel Disease (online only)
The Medical Letter on Drugs and Therapeutics • July 2, 2018; (Issue 1550)
...
View Expanded Table: Some Drugs for Inflammatory Bowel Disease
Table: Drugs for Crohn's Disease (online only)
The Medical Letter on Drugs and Therapeutics • July 2, 2018; (Issue 1550)
...
View Table: Drugs for Crohn's Disease
Table: Safety of Drugs for IBD in Pregnancy (online only)
The Medical Letter on Drugs and Therapeutics • July 2, 2018; (Issue 1550)
...
View Table: Safety of Drugs for IBD in Pregnancy
Guselkumab (Tremfya) for Psoriasis
The Medical Letter on Drugs and Therapeutics • November 6, 2017; (Issue 1533)
The FDA has approved the interleukin (IL)-23 blocker
guselkumab (Tremfya – Janssen) for treatment of
moderate to severe plaque psoriasis in adults who
are candidates for systemic therapy or...
The FDA has approved the interleukin (IL)-23 blocker
guselkumab (Tremfya – Janssen) for treatment of
moderate to severe plaque psoriasis in adults who
are candidates for systemic therapy or phototherapy.
Guselkumab is the first selective IL-23 blocker to
become available in the US.
Brodalumab (Siliq) - Another IL-17A Antagonist for Psoriasis
The Medical Letter on Drugs and Therapeutics • July 17, 2017; (Issue 1525)
The FDA has approved brodalumab (Siliq – Valeant),
an injectable human interleukin (IL)-17A receptor
antagonist, for treatment of adults with moderate to
severe plaque psoriasis who have failed to...
The FDA has approved brodalumab (Siliq – Valeant),
an injectable human interleukin (IL)-17A receptor
antagonist, for treatment of adults with moderate to
severe plaque psoriasis who have failed to respond
to other systemic therapies. Brodalumab is the third
IL-17A antagonist to be approved in the US for this
indication; secukinumab (Cosentyx) and ixekizumab
(Taltz) were approved earlier.
Ustekinumab (Stelara) for Crohn's Disease
The Medical Letter on Drugs and Therapeutics • January 2, 2017; (Issue 1511)
The FDA has approved the human interleukin (IL)-12
and -23 antagonist ustekinumab (Stelara – Janssen
Biotech) for treatment of moderately to severely active
Crohn's disease in adults who were intolerant of...
The FDA has approved the human interleukin (IL)-12
and -23 antagonist ustekinumab (Stelara – Janssen
Biotech) for treatment of moderately to severely active
Crohn's disease in adults who were intolerant of or
whose disease was unresponsive to treatment with immunomodulators
or corticosteroids, or a tumor necrosis
factor (TNF) inhibitor. Ustekinumab was approved earlier
for treatment of psoriasis and psoriatic arthritis.
Ixekizumab (Taltz) - A Second IL-17A Inhibitor for Psoriasis
The Medical Letter on Drugs and Therapeutics • May 9, 2016; (Issue 1494)
The FDA has approved ixekizumab (Taltz – Lilly), an
injectable humanized interleukin (IL)-17A antagonist,
for treatment of adults with moderate to severe plaque
psoriasis who are candidates for systemic...
The FDA has approved ixekizumab (Taltz – Lilly), an
injectable humanized interleukin (IL)-17A antagonist,
for treatment of adults with moderate to severe plaque
psoriasis who are candidates for systemic therapy
or phototherapy. Ixekizumab is the second IL-17A
antagonist to be approved for this indication in the US;
secukinumab (Cosentyx – Novartis) was the first.
Drugs for Psoriasis
The Medical Letter on Drugs and Therapeutics • June 8, 2015; (Issue 1470)
Mild to moderate psoriasis is generally treated with
topical corticosteroids. Vitamin D analogs and tazarotene
are topical alternatives that can be used in combination
with topical corticosteroids....
Mild to moderate psoriasis is generally treated with
topical corticosteroids. Vitamin D analogs and tazarotene
are topical alternatives that can be used in combination
with topical corticosteroids. Phototherapy and systemic
therapy, including biologic agents, are recommended for
patients with moderate to severe disease.
Drugs for Psoriatic Arthritis (online only)
The Medical Letter on Drugs and Therapeutics • June 8, 2015; (Issue 1470)
Psoriatic arthritis is a chronic inflammatory arthropathy
that develops in up to 40% of patients with
psoriasis. Several guidelines for treatment of psoriatic
arthritis have been...
Psoriatic arthritis is a chronic inflammatory arthropathy
that develops in up to 40% of patients with
psoriasis. Several guidelines for treatment of psoriatic
arthritis have been published.
Secukinumab (Cosentyx) for Psoriasis
The Medical Letter on Drugs and Therapeutics • March 30, 2015; (Issue 1465)
Secukinumab (Cosentyx – Novartis), an injectable
human interleukin (IL)-17A antagonist, has been
approved by the FDA for treatment of moderate to
severe plaque psoriasis in adult patients who...
Secukinumab (Cosentyx – Novartis), an injectable
human interleukin (IL)-17A antagonist, has been
approved by the FDA for treatment of moderate to
severe plaque psoriasis in adult patients who are
candidates for systemic therapy or phototherapy.
It is the first IL-17 inhibitor to be approved for any
indication in the US.
Apremilast (Otezla) for Psoriatic Arthritis
The Medical Letter on Drugs and Therapeutics • May 26, 2014; (Issue 1443)
Apremilast (Otezla – Celgene), an oral phosphodiesterase
type-4 (PDE4) inhibitor, has been approved
by the FDA for treatment of active psoriatic arthritis in
adults. It is the fi rst PDE4 inhibitor to be...
Apremilast (Otezla – Celgene), an oral phosphodiesterase
type-4 (PDE4) inhibitor, has been approved
by the FDA for treatment of active psoriatic arthritis in
adults. It is the fi rst PDE4 inhibitor to be approved for this
indication.
Certolizumab Pegol (Cimzia) and Ustekinumab (Stelara) for Psoriatic Arthritis
The Medical Letter on Drugs and Therapeutics • February 3, 2014; (Issue 1435)
Certolizumab pegol (Cimzia – UCB), a tumor necrosis
factor (TNF) inhibitor previously approved for treatment
of Crohn's disease and rheumatoid arthritis,
and ustekinumab (Stelara – Janssen), a human...
Certolizumab pegol (Cimzia – UCB), a tumor necrosis
factor (TNF) inhibitor previously approved for treatment
of Crohn's disease and rheumatoid arthritis,
and ustekinumab (Stelara – Janssen), a human interleukin-12 and -23 antagonist previously approved for
treatment of moderate-to-severe plaque psoriasis,
have now been approved by the FDA for treatment of
active psoriatic arthritis.
Drugs for Acne, Rosacea and Psoriasis
The Medical Letter on Drugs and Therapeutics • January 1, 2013; (Issue 125)
The pathogenesis of acne is multifactorial: follicular
hyperkeratinization, bacteria, sebum production,
androgens, and inflammation all play a role. The gram-positive
microaerophilic bacteria...
The pathogenesis of acne is multifactorial: follicular
hyperkeratinization, bacteria, sebum production,
androgens, and inflammation all play a role. The gram-positive
microaerophilic bacteria Propionibacterium
acnes promote development of acne lesions by secreting
chemotactic factors that attract leukocytes to the
follicle, causing inflammation.
Addendum: Cost of Ustekinumab (Stelara)
The Medical Letter on Drugs and Therapeutics • March 8, 2010; (Issue 1333)
In the Medical Letter article on ustekinumab (Stelara) for psoriasis (2010; 52:7), footnote 2 in table 2 should have included a second sentence: $5595.60 is the cost of one 45-mg...
In the Medical Letter article on ustekinumab (Stelara) for psoriasis (2010; 52:7), footnote 2 in table 2 should have included a second sentence: $5595.60 is the cost of one 45-mg syringe.
Drugs for Acne, Rosacea and Psoriasis
The Medical Letter on Drugs and Therapeutics • November 1, 2008; (Issue 75)
The pathogenesis of acne is multifactorial: follicular hyperkeratinization, bacteria, sebum production, androgens and inflammation all play a role. The gram-positive microaerophilic bacteria Propionibacterium...
The pathogenesis of acne is multifactorial: follicular hyperkeratinization, bacteria, sebum production, androgens and inflammation all play a role. The gram-positive microaerophilic bacteria Propionibacterium acnes promote development of acne lesions by secreting chemotactic factors that attract leukocytes to the follicle, causing inflammation.